Pharmaceutical Consulting

Pharma Agency Consulting firm Experts Specialists Consultancy

For more than 30 years, our specialized team has been supporting everyday pharmaceutical industry leaders in their innovation and new market development projects.

    Tell us about your uncharted territory

    You have a project and want to discuss it with our explorers, write us!

    One of our explorers will contact you shortly.

    They trust us


    How we support players in the pharmaceutical industry

    Founded in 1993, Alcimed is a consulting firm specialized in innovation and new markets development in life sciences. Spread over our 8 offices in the world (in France, Europe, Singapore and the USA), our team of 220 high-level explorers supports everyday decision-makers and business departments (marketing, research, innovation, strategy, CSR, etc.) in their innovation and new market development projects.

    Our projects for Pharma players cover topics as diverse as new technologies and therapeutic approaches, preparing for new drug launches, understanding disease management and care pathways, assessing market and licensing opportunities, market access, regulatory framework analysis, and much more!

    And our activities are not limited to the pharmaceutical industry. The diversity of our clients (manufacturers, ETIs, innovative start-ups, institutions, etc.), the subjects we deal with, and the geographical areas we explore, enable us to master a wide range of missions and develop recognized expertise in our specialized sectors.

    Our missions

    Our expertise

    What they say

    • TCV_biomerieux_miniature_site_EN_min

      Renaud JONQUIERES

      Sr Vice President R&D Portfolio and Open Innovation

    • TCV_sanofi_miniature_site_EN_min

      Cyril SAVY

      Solution Lead Diabete Division

    • Logo_carre_Boehringer_Ingelheim

      "The Alcimed team’s support has enabled Boehringer Ingelheim to move forward efficiently on several projects in a structured way over the past two years. The Alcimed team brought a good level of strategic thinking, an open-mindedness and a willingness to entertain new ideas. These assets enabled Alcimed to successfully challenge internal teams and co-build solutions with them. In the same way, the creation of the VPH Hub in Lyon, accompanied by many players in the Lyon Healthcare ecosystem, has progressed in a more organized and efficient way thanks to a team that is both structuring, structured, and ... friendly."

      Erick LELOUCHE

      President Boehringer Ingelheim France

    • Logo_carre_MundiPharma

      "I had the chance to work with the Alcimed team in preparing the launch of our first biosimilar in France. Alcimed's support was particularly valuable as it allowed us to have a perfect alignment between the definition of our strategy and its execution, which ultimately contributed to the success of this launch (our product became market leader 12 months after its launch). Alcimed's approach based on a rigorous methodology and the constant search for innovative solutions also allowed us to reinforce the expertise of our internal teams and to create a positive work dynamic. I hope that I will have other opportunities in the future to work with Alcimed's Healthcare team."

      Benoit SLAVICEK

      Global VP ExCom member

    • Logo_carre_Striker

      "Very engaging and rich project! The beginning of a beautiful friendship between Stryker and Alcimed!"

      Paul EVITT

      General Manager Trauma & Extremities

    Examples of projects carried out for our clients in the pharmaceutical industry

    • Project roadmap for the launch of an orphan drug in Europe

      Alcimed assisted an American biopharmaceutical client in defining the launch strategy of its orphan drug in Europe, and then in structuring a concrete and operational plan, both at the level of the European region and at the level of each targeted country.

      The launch plan is a roadmap for each of the company’s key functions (medical, marketing, production, regulatory, sales) and covers the period from pre-launch (before obtaining the MA – Marketing Authorization) to the first sales.

      Today, our team is still involved in regularly updating the first plan defined with our client, according to internal or external developments around this orphan drug in several European countries.

    • Prospective study: evolution of the role of the pharmaceutical sales representative in the pharmaceutical industry

      We supported a leading pharmaceutical company in a prospective analysis of the role of the medical sales representative of the future. Our client, the company’s sales director, was faced with a context of changing customer engagement practices and wanted to draw up a vision of what the pharmaceutical sales representative’s job of the future might be.

      We helped him to define a vision for 2030 and to build a roadmap with the different projects to be implemented to make his teams evolve towards this new role. We first led several working sessions with all the stakeholders involved in the different projects to identify the objectives, key steps, levers, resources, means, timing, indicators, expected deliverables and the functions involved for each project.

      Then, we formalized this roadmap to facilitate its diffusion internally and to communicate on the next steps.

    • Analyzing the environmental impact of transitioning from a traditional clinical development model to a fully digital model

      Alcimed helped a leading pharmaceutical player in analyzing the environmental impact linked to their transition initiative towards digital therapeutic trials.

      Our help involved defining a model of comparison between different modes of clinical studies, both traditional and digital, by conducting a life cycle analysis focused on different groups of activities: travel and transportation, waste disposal, data production and storage. This model shed light on differences in climate impact, as well as their effects on human health, resource consumption (fossil energy, mineral raw materials, water), and biodiversity.

      This project allowed our client to find and put in place improvement strategies to reduce the environmental impact of digital clinical trials worldwide.

    • Pharma market access: preparation for the launch of a new CAR-T therapy

      We assisted a leading pharmaceutical company in the field of CAR-T therapies in preparing the launch of its new treatment and in defining its market access strategy in the United States, Canada and Europe. CAR-Ts are highly personalized technologies that require a high level of specialization to be delivered to patients, and therefore not all healthcare centers are ready to administer them. In this context, and in order to define the market access strategy for its new treatment, we helped our client to:

      1. Understand and identify which centers would have the capacity to bring CAR-Ts to market.
      2. Analyze the bottlenecks for approval in the in-scope markets.
      3. Consequently, define the actions to be implemented to ensure access to its new CAR-T therapy.

      After an investigation conducted in more than 200 healthcare centers in the United States, Canada and Europe, our analysis brought us to recommend to our client the next key steps to be taken in order to develop the skills of each center and to promote rapid access to their new treatment.

    • Rethinking the innovation process of a pharmaceutical company for greater agility

      Our team assisted a pharmaceutical player who found that his innovation process was not agile and efficient enough.

      We first exchanged with our client’s teams to get a detailed understanding of what was working well and to identify the malfunctions of the initial process. Then, we identified inspiring cases from industries outside healthcare but facing the same issues and we defined the guiding principles of the new process to be implemented.

      With this material, we organized a “Sprint” bringing together about twenty representatives from the various departments and functions involved in innovation, in order to co-build the new model following the precepts of Design Thinking.

      Ultimately, this work enabled us to co-construct with our client’s teams their new innovation process, more focused and more agile at the same time, allowing more disruption and empowerment of the teams!

    • Optimizing the emotional journey of patients with rare diseases

      One of our clients, a leading pharmaceutical company, wanted to improve the care of patients suffering from a rare disease by developing a high value-added service offering that would improve their well-being or quality of life throughout their care pathway (from diagnosis to palliative care).

      To do this, our team interviewed patients, patient support workers and associations in each country involved in order to map their emotions and to identify the levers for improving their well-being and quality of life that could be addressed by developing services. Following this, our team pre-tested these service ideas with healthcare professionals, before organizing a workshop to co-construct a service development roadmap with our client’s medical and marketing teams.

      Ultimately, several services were deployed in the pilot countries and then extended to other countries in the zone, improving the emotional pathway of patients and positioning our client as a major player in public health.

    • R&D and translational research strategies for a pharmaceutical laboratory

      Our client, a leading pharmaceutical laboratory in the ophthalmology market, was lacking in reasons to decide whether or not to develop a translational research programs in its R&D strategy. We helped them in exploring the primary barriers and the associated levers to put in place in translational research, focusing mainly on benchmark cases. Our studies focused on three main points:

      1. Identifying good practices for a pharmaceutical company to implement translational research activities
      2. Determining the potential of applying translational research in the ophthalmology field
      3. Defining the optimal organization of our client’s resources

      In the end, our study enabled the client to have a complete vision on the ins and outs of translational research programs and the potential implications that their implementation could have on their global R&D strategy.

    • Identification and characterization of the impacts of eco-design on the ecosystem of a health player

      We supported a leading pharmaceutical player in a project aiming to study the impact of eco-designing their medications on their ecosystem (doctors, hospitals, pharmacists, patient associations, payers, regulators, etc).

      Through an in-depth external investigation, our team measured the impact of ecological design levers on the entire life cycle of our client’s products, and provided a set of recommendations on priority actions to be integrated in the short, medium, and long term, with the aim of transforming our client’s development strategy into a green design approach.

    You have a project?

      Tell us about your uncharted territory

      You have a project and want to discuss it with our explorers, write us!

      One of our explorers will contact you shortly.

      To go further